Abstract Anti-cancer tyrosine kinase inhibitors (TKIs) are effective in many types of cancers including non-small cell lung cancer, while appearance of TKI-resistant tumors suggests a need for the development of their potentiation strategies. We have previously shown that a methoxyflavanone derivative from the Asian medicinal herb Perilla frutescens (Perilladerived methoxyflavanone; PDMF) shows a prominent anti-tumor activity against A549 human lung adenocarcinoma. Here we show that PDMF and anticancer TKIs (nilotinib, bosutinib, dasatinib, and ponatinib) synergistically suppress proliferation of A549 cells. Flow cytometric analysis indicated that co-stimulation with nilotinib (4 lM) and PDMF induced G 2 /M cell cycle arrest in low PDMF doses (10-50 lM), whereas this combination triggered de novo G 1 arrest in higher PDMF dosages (50-125 lM). We also found that co-administration with nilotinib and PDMF significantly suppressed in vivo tumorigenicity of A549 cells in athymic nude mice.
Introduction
Lung cancer is the leading cause of cancer-associated mortality worldwide (Siegel et al. 2013 ). In the clinical practice, lung carcinomas are divided into two main histological types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), where the other accounts for 80% of total lung cancer cases (Meoni et al. 2013) . The main characteristic of NSCLC is its high aggressive invasion and metastatic properties. Therefore, the majority of advanced NSCLC cases require receiving combination of chemotherapy, and/ or radiation treatment (Molina et al. 2008) . Tyrosine kinase inhibitors (TKIs) are now the golden stone of treatment in NSCLC (Gridelli et al. 2014) . These drugs target biological functions that cancer cells are critically reliant on, ultimately causing tumor shrinkage (Krause and Van Etten 2005) . However, a serious problem is that many of patients who especially receive the epidermal growth factor receptor (EGFR)-TKI therapy get resistance to the agents (Rosell et al. 2009 ), suggesting a need for the development of other chemotherapeutic drugs. Thus, there remains a need for strategies to safely increase the effectiveness of TKIs.
Recently, a considerable attention has been given to the identification of new therapeutic agents that show synergistic effect with TKIs as a promising direction to overcome the above-mentioned problems. In general, combination therapies not only potentiate the therapeutic efficacy of each agent alone, but also enable the use of reduced doses (Milano et al. 2009; Nautiyal et al. 2011) . In this context, plant flavonoids, especially those from dietary sources, are commonly perceived as non-toxic, well-tolerated, easily available, and inexpensive compounds that can target multiple cellular pathways (Surh 2003; Sak 2012) . It has been shown that flavonoids have anti-tumor activities through induction of apoptosis and cell cycle arrest of tumor cells (Szliszka et al. 2008; Kim et al. 2013 ). In particular, flavanones are a type of flavonoids that exhibit chemo-preventive and anticancer properties (Graf et al. 2005) . Previous in vitro studies showed that naturally-occurring flavanones have anti-tumor activity against human cancer cells; e.g. naringenin in THP-1 and U937 leukemia cells (Park et al. 2008b; Jin et al. 2009 ), hesperidin in SNUC4 colon cancer and NALM6 leukemia cells (Park et al. 2008a; Ghorbani et al. 2012) , and liquiritigenin in SMMC7721 hepatocarcinoma and HeLa cervical cancer cells (Zhang et al. 2009; Liu et al. 2011) . Flavanones also received a considerable attention as these agents may potentiate the cytotoxic effects of chemotherapy and radiotherapy, protect normal cells from therapy-associated toxicity, increase a systemic bioavailability of cytostatic agents, and in some cases, even overcome chemoresistance (Garg et al. 2005; Kuno et al. 2012) .
Recently, our group has identified a new class of methoxyflavanone derivative (8-hydroxy-5,7-dimethoxyflavanone) from the Asian dietary herb, Perilla frutescens (named Perilla-derived methoxyflavanone, PDMF). PDMF selectively suppresses Akt activation to inhibit type I hypersensitivity reactions (Kamei et al. 2017) . We also have found that PDMF shows prominent tumor suppressive activity on A549 human adenocarcinoma through induction of p53-driven G 2 /M cell cycle arrest and apoptosis (Abd ElHafeez et al. unpublished data) . In the present study, we show a synergistic tumor-suppressive potency of PDMF and anti-cancer TKIs on A549 cells in vitro as well as in vivo.
Materials and methods

Cell cultures and reagents
The A549 human lung adenocarcinoma was obtained from the RIKEN CELL BANK (Tsukuba, Japan), and was cultured in Dulbecco's-modified Eagle's medium (DMEM; Life Technologies, Tokyo, Japan) containing 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA), 100 U/ml penicillin, and 100 lg/ ml streptomycin (Life Technologies) in a humidified atmosphere with 5% CO 2 at 37°C. Perilla-derived methoxyflavanone (PDMF; 8-hydroxy-5,7-dimethoxyflavanone) (Kamei et al. 2017 ) was chemically synthesized by Tokyo Chemical Industry (Tokyo, Japan). Nilotinib, bosutinib, dasatinib, and ponatinib were purchased from LC laboratories (Woburn, MA, USA). Doxorubicin was purchased from Sigma-Aldrich. All chemicals used in this study were of analytical or cell culture grade.
Cell proliferation assay
Cell proliferation was analyzed by BrdU incorporation using a Colorimetric Cell Proliferation ELISA, BrdU Kit (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. A549 cells were seeded at 5 9 10 3 cells/well and cultured overnight in a 96-well plate. The cells were then treated with sub-optimal doses of PDMF alone (10, 50, 100 or 125 lM), or in combination with sub-optimal doses of Bcr-Abl TKIs (4 lM nilotinib, 1 lM bosutinib, 50 nM dasatinib or 0.5 lM ponatinib) for 24 h. The doses of PDMF and TKIs were determined by a preliminary dose-response study on A549 cells, in which reduction in cell proliferation is limited up to 20%. A549 cells were also treated with either 1 lM doxorubicin as a positive control or dimethyl sulfoxide (DMSO, vehicle) as a negative control. BrdU was added to a final concentration of 10 lM and cultured for the last 2 h.
Drug interaction analysis
To evaluate whether the anti-tumor effects of the combination of PDMF and TKIs were synergistic, the drug interactions were analyzed based on the combination index method of Chou and Talalay (1984) 
Animal experiments
All animal experiments were carried out using protocols approved by the Committee on Animal Experimentation of Hiroshima University, Japan. Fourweek-old female BALB/c nude mice were purchased from Charles River Laboratories Japan (Kanagawa, Japan), and kept under specific pathogen-free conditions.
For construction of A549 cell xenograft model, BALB/c nude mice (n = 42) were subcutaneously (s.c.) injected with 5 9 10 6 A549 cells into their dorsal skins. The mice were then randomly divided into seven groups (six mice each), and s.c. administered with 40 ll of 0.5% DMSO in PBS (control), 10 lM PDMF (6.4 ng/g murine body weight), 125 lM PDMF (79.7 ng/g body weight), 4 lM nilotinib (4.5 ng/g body weight), 4 lM nilotinib with 10 lM PDMF, 4 lM nilotinib with 125 lM PDMF, or 20 lM nilotinib (22.5 ng/g body weight). Those agents were started to be injected every three days from the next day of the A549 cell transplantation. On day 18, tumor volumes were started to be monitored every three days. Tumor volume was calculated as (wide 2 9 length)/2 of formulated tumor (Tomayko and Reynolds 1989) . On day 36, mice were sacrificed and their final tumor weights were quantified.
Statistical analysis
Data are represented as mean ± SD. Student's t test was performed to determine the statistical significance compared to corresponding controls. Statistical significance was defined as P \ 0.05 or P \ 0.005. The data shown in the figures are representative data for three independent experimental results.
Results and discussion
PDMF and anti-cancer TKIs synergistically suppress cell proliferation of A549 human lung cancer cells A549 human lung adenocarcinoma cells are used as a model of EGFR-TKI-resistant NSCLC cells (Ito et al. 2014; Cao et al. 2016 ). For those EGFR-TKI-resistant cells, the Bcr-Abl type of TKIs may offer alternative anti-cancer agent, since the EGFR-TKI-resistant A549 cells indeed show a good response to a Bcr-Abl TKI (Zhang et al. 2003) , probably because of its crossreaction to a wide array of oncogenic TKs. For those reasons, here we decided to analyze the combination anti-tumor effect of Bcr-Abl TKIs (nilotinib, bosutinib, dasatinib and ponatinib) and PDMF on A549 cells.
To test whether combination of PDMF and TKIs presents a synergistic anti-cancer effect, A549 cells were stimulated with serial doses of PDMF (10, 50, 100, and 125 lM) and sub-optimal doses of TKIs (nilotinib, bosutinib, dasatinib and ponatinib). BrdU incorporation assay revealed that those combination regimens resulted in a greater loss of the cell proliferation compared to the individual agents, suggesting a synergistic growth inhibitory effect of PDMF and TKIs on A549 cells (Fig. 1) . To further confirm the synergism, interactions between PDMF and TKIs were analyzed with the median-effect principle of Chou and Talalay (1984) We next analyzed impact of the PDMF/nilotinib costimulation on cell cycle progression of A549 cells. Flow cytometric analysis indicated that low doses of PDMF (10-50 lM) and nilotinib (4 lM) synergistically induced G 2 /M cell cycle arrest in A549 cells (Fig. 2a, b) . Intriguingly, we found that co-stimulation with higher doses of PDMF (50-125 lM) synergized with nilotinib to induce de novo G 1 cell cycle arrest (Fig. 2a, b) , suggesting that the synergistic anti-cancer effect of PDMF and nilotinib is executed by a twostage cell cycle arrest depending on the PDMF dosages. We also found that the PDMF co-stimulation had no effect on apoptosis induction in A549 cells 
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Fig. 1 PDMF and anti-cancer TKIs synergistically suppress proliferation of A549 human lung adenocarcinoma. Inhibitory effects of sub-optimal doses of PDMF (10-125 lM), suboptimal doses of Bcr-Abl TKIs (4 lM nilotinib, 1 lM bosutinib, 0.05 lM dasatinib, or 0.5 lM ponatinib), and their combinations on the proliferation of A549 cells were determined by BrdU incorporation assay. The sub-optimal doses of PDMF and TKIs were determined by a preliminary dose-response study on A549 cells, in which a reduction in cell proliferation is limited up to 20%. Doxorubicin (1 lM, DNA damaging agent) and dimethyl sulfoxide (DMSO, vehicle) are set as a positive and negative vehicle controls, respectively. Representative data of three independent experiments are shown as mean ± SD of three replicates. *P \ 0.05 and **P \ 0.005 indicate significant differences assessed by Student's t test ( Supplementary Fig. 1 ), suggesting that the synergistic tumor suppressive effect is mainly fulfilled through augmentation of G 1 and G 2 /M cell cycle arrest. Mechanisms underlying the PDMF/nilotinib-driven G 1 (high PDMF doses) and G 2 /M (low PDMF doses) cell cycle arrest are currently unknown. Our preliminary data indicate that co-stimulation with a high dose PDMF (125 lM) synergized with nilotinib to induce cyclin-dependent kinase (CDK) inhibitor p21, whereas a low dose PDMF (10 lM) and nilotinib synergistically decreased protein levels of CDK1 and cyclin B1, that form a hallmark cyclin/CDK complex in the G 2 /M cell cycle checkpoint (data not shown). Thus, one possible explanation is that the synergistic two-stage cell cycle arrest could be fulfilled through direct upand down-modulation of those G 1 and G 2 /M cell cycle checkpoint molecules. Another critical issue is that a possible anti-cancer effect after more than 24 h remains to be investigated in the present study. Further rigorous analysis is needed to elucidate the precise mechanisms by which the co-stimulation with nilotinib and PDMF fulfills anti-tumor potency. Co-administration with PDMF and nilotinib suppresses tumorigenicity of A549 cells in athymic nude mice
To further test the synergistic anti-tumor effect of PDMF and nilotinib in vivo, we co-administered PDMF and nilotinib to an A549 cell-xenograft model on athymic nude mice. We found that co-treatment with PDMF and nilotinib significantly impaired tumorigenicity of A549 cells as compared to nilotinib alone or PDMF alone (Fig. 3a) ; especially, co-administration with 125 lM PDMF markedly suppress in vivo tumor development. The PDMF co-treatment also significantly decreased final A549 tumor weight in a dose-dependent manner (Fig. 3b) . These results suggest that co-administration with PDMF and nilotinib to cancer-adjacent sites prevent in vivo tumorigenesis of A549 cells. To further gain insight into the application of PDMF, oral and/or systemic administration study of PDMF and nilotinib should be conducted in the next studies. Another unsolved issue is safety and specificity of the PDMF/nilotinib combination. We preliminary observe that PDMF by itself is less cytotoxic to WI-38 human normal lung fibroblast cells than to A549 cells (Abd El-Hafeez et al., unpublished data), but cancer selectivity as well as safety issue of the combination regimen should be overcome in future studies.
In conclusion, here we show that a P. frutescensderived flavanone derivative (PDMF) synergizes with anti-cancer TKI to augment tumor suppressive potency on A549 human adenocarcinoma in vitro as well as in vivo. Mechanistically, the synergistic antitumor effect is fulfilled by the induction of a two-stage Mice were then randomly assigned to seven groups (six mice per group) that were s.c. administered with 40 ll of 0.5% DMSO in PBS (control), 10 lM PDMF (6.4 ng/g murine body weight), 125 lM PDMF (79.7 ng/ g body weight), 4 lM nilotinib (4.5 ng/g body weight), 4 lM nilotinib with 10 lM PDMF, 4 lM nilotinib with 125 lM PDMF, or 20 lM nilotinib (22.5 ng/g body weight). 18 days after xenotransplantation, tumor volumes were monitored each three days (a). On day 36, mice were euthanized and final tumor weights were quantified (b). *P \ 0.05 indicates significant difference compared with nilotinib only (4 lM) cell cycle arrest at G 1 and G 2 /M phases. Further investigation is required to develop the combinational cancer preventive strategies utilizing PDMF and anticancer TKIs.
